Interview: Lee-Cheng Liu, President & CEO, EirGenix, Taiwan
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Address:
Tel: 886-2-2655-8133
In view of the need for an inter-agency task to carry out the promotion of the biotechnology and pharmaceutical high-tech industries, in November 1995 the Executive Yuan approved the key points for establishing the Biotechnology and Pharmaceutical Industries Program Office (BPIPO, MOEA). In February 1996 the BPIPO was formerly established to implement and promote the biotechnology industry’s development policy and act as a bridge for communication, coordination and integration among agencies. In December 2001, The Executive Yuan’s One-Stop-Service Office for the Biotechnology Industry was established under the BPIPO, with the office being responsible for the integration and coordination of local organizations involved in the various biotech-related approval and application processes, to build up a sound development environment for the biotech industry. The Director of the Industrial Development Bureau, MOEA acted as convener of the Program Office and formed a committee including the heads of the Executive Yuan’s Department of Health; Environmental Protection Administration; Council for Economic Planning and Development; National Science Council; Council of Agriculture; Science & Technology Advisory Group (STAG); Committee for the Development Fund; Department of Industrial Technology, MOEA; Intellectual Property Office, MOEA; and related government agencies; and representatives, academics, and experts from major research organizations and industry to form an inter-agency promotional organization.
The role of the Program Office is to serve as a window for the exchange of vital information between domestic and foreign industry, and to aggressively promote investment in Taiwan. In so doing, the Program Office hopes to accelerate the upgrading of Taiwan’s biotechnology and pharmaceutical industries and promote Taiwan to become an R&D, manufacturing and operations center for the Asia Pacific region, and furthermore to forge ahead to establish a global operations center.
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry…
Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent…
Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the…
Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where…
James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech…
Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company…
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage…
The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development…
General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved…
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The chairman of Taipei Medical University (TMU) discusses the key challenges TMU has faced over the years, how these challenges will continue to affect the future, and what international accreditation…
See our Cookie Privacy Policy Here
